A global healthcare executive joins Nox Health to lead the company’s next phase of growth, while the founder transitions to vice chairman.
Key takeaways:
- Nox Health has appointed a new CEO effective June 15, 2026, to drive global expansion.
- The former CEO will transition to founder and vice chairman to focus on innovation and long-term strategy.
- The incoming leader brings extensive experience in scaling technology-enabled healthcare and data businesses.
Nox Health announced the appointment of Milton Silva-Craig as its new CEO, effective June 15, 2026.
Silva-Craig succeeds Sigurjón Kristjánsson, who has led the company since its founding. Kristjánsson will continue as founder and vice chairman, focusing on innovation, long-term strategy, and new growth initiatives.
Silva-Craig is a global healthcare executive with a track record of scaling technology-enabled healthcare and data businesses in both private equity and public company environments. Most recently, he served as CEO of Q-Centrix, an enterprise clinical data management platform serving multi-hospital health systems. Prior to Q-Centrix, Silva-Craig held senior leadership positions spanning global healthcare operations, enterprise commercialization, and product development.
“Sleep health is rapidly emerging as one of healthcare’s most important frontiers for improving outcomes and reducing the burden of chronic disease,” says Silva-Craig, new CEO, in a release. “The industry is moving beyond episodic testing toward longitudinal, outcomes-based sleep health management, creating a significant opportunity for innovation and impact. What attracted me to Nox is its uniquely integrated platform, combining diagnostics, AI-enabled interpretation, patient engagement, and care management at enterprise scale.”
“The opportunity ahead for sleep healthcare is extraordinary,” says Kristjánsson, founder and vice chairman, in a release. “Over the last decade, we have built a differentiated platform grounded in science, innovation, and real-world outcomes. Milton’s experience scaling complex healthcare organizations globally positions Nox exceptionally well for our next phase of growth, while enabling me to focus even more deeply on innovation, long-term strategy, and helping shape the future direction of the company.”
Vestar Capital Partners, which led a strategic growth investment in Nox in 2022, has partnered with the company to accelerate the development of its sleep diagnostic technology and services, as well as expand the adoption of its sleep management solutions for employers and health plans.
“Since Vestar’s investment, the company has nearly doubled in size while establishing itself as a global leader in sleep diagnostics and sleep care management,” says Roger Holstein, chairman of the board and managing director of Vestar Capital Partners, in a release. “The convergence of sleep science, AI-enabled healthcare, and growing demand for measurable outcomes creates a unique opportunity for Nox to expand its impact globally.”
